Drug Trial Radar · NCT06246916
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Sep 9, 2024
Primary completion
Mar 22, 2027
Study completion Jul 10, 2033
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)
Conditions
- Melanoma
Interventions
fianlimabDrug
Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab
cemiplimabDrug
IV administration Q3W in combination with fianlimab
relatlimab+nivolumabDrug
IV administration every 4 weeks (Q4W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on blinded independent central review (BICR)Time frame: Up to 72 months
Locations
113 sites in 2 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers
Chandler, Arizona · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Arizona Oncology Associates
Tucson, Arizona · Withdrawn
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Withdrawn
Providence Medical Foundation
Fullerton, California · Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California · Recruiting
University of California Los Angeles
Los Angeles, California · Recruiting
St. Joseph Hospital Orange
Orange, California · Recruiting
University of California Irvine, UCI Medical Center
Orange, California · Recruiting
Eisenhower Medical Center
Rancho Mirage, California · Withdrawn
Emad Ibrahim, MD, Inc.
Redlands, California · Recruiting
Sutter Health
Sacramento, California · Recruiting
University of California San Francisco (UCSF)
San Francisco, California · Recruiting
Sansum Clinic
Santa Barbara, California · Withdrawn
St John's Cancer Institute
Santa Monica, California · Withdrawn
Rocky Mountain Regional VA Medical Center
Aurora, Colorado · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
The Melanoma And Skin Cancer Institute
Englewood, Colorado · Recruiting
UCHealth
Fort Collins, Colorado · Withdrawn
Yale Cancer Center
New Haven, Connecticut · Recruiting
Clermont Oncology Center
Clermont, Florida · Withdrawn
Mayo Clinic Florida
Jacksonville, Florida · Recruiting
Cancer Specialist of North Florida
Jacksonville, Florida · Withdrawn
Boca Raton Clinical Research (BRCR) Global
Tamarac, Florida · Recruiting
H. Lee Moffitt Cancer Center
Tampa, Florida · Recruiting
University Cancer & Blood Center
Athens, Georgia · Recruiting
John B. Amos Cancer Center
Columbus, Georgia · Withdrawn
Beacon Clinic
Coeur d'Alene, Idaho · Recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois · Recruiting
Advocate Lutheran General Hospital
Park Ridge, Illinois · Recruiting
Illinois CancerCare
Peoria, Illinois · Recruiting
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana · Recruiting
The University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Markey Cancer Center Clinical Research Organization
Lexington, Kentucky · Completed
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Withdrawn
Maryland Oncology Hematology, P.A.
Columbia, Maryland · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Withdrawn
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, Michigan · Recruiting
Minnesota Oncology Hematology, P.A
Fridley, Minnesota · Recruiting
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.